These data suggest that LSD1 and HDACs cooperatively modulate the key pathways of GBM cell death and verify the combined administration of LSD1 and HDAC inhibitors as a therapeutic strategy for GBM. The gene discussed is HDAC9; the disease is glioblastoma.